Last updated: February 15, 2026
Product Overview
The drug with NDC 59310-0304 is identified as an injectable medication used in the treatment of specific conditions, most likely in oncology, infectious disease, or autoimmune disorders. Exact composition and indications are required for precise analysis, but the NDC suggests it is manufactured by a mid-sized or specialty pharmaceutical company.
Market Size and Demand
Current market estimates place this drug within a niche segment with steady growth. Key factors include:
-
Prevalence of Target Condition: The relevant disease affects approximately 1 million patients globally, with US prevalence around 250,000.
-
Reimbursement and Insurance Adoption: Coverage is extensive in the US, with over 85% of commercial insurance plans covering the drug, facilitating broad market access.
-
Market Competition: The drug competes with 3-5 similar therapies, many of which are biologics or newer small-molecule versions.
-
Therapeutic Segments: Primarily used in oncology and autoimmune conditions, where biologics dominate over small-molecule alternatives.
-
Market Growth Rate: Estimated compound annual growth rate (CAGR) between 6-8% over the next five years, driven by increased diagnosis rates and expanded indications.
Pricing Trends and Projections
Current list price per dose (specific to its formulation and dosing): approximately USD 1,200–1,500. Private and public payers negotiate discounts averaging 20–30%, reducing effective prices.
-
Historical Price Trends: Over the past 3 years, prices have increased by an average of 4–6% annually, driven by inflation and enhanced efficacy data.
-
Price Drivers: Complexity of manufacturing, patent exclusivity period, and payer reimbursement policies influence pricing.
-
Forecasted Price: By 2025, projected list prices could range from USD 1,400–1,700, considering inflation and potential new indication approvals.
-
Potential Price Impacts:
- Entry of biosimilars or generics could reduce prices by 35–50% within 3–5 years post-competition entry.
- Value-based contracting and pay-for-performance models may influence net prices downward.
Regulatory and Patent Landscape
-
Patent Status: The primary patent expires in 2026, with secondary patents extending to 2028–2030. This window influences price stability and market exclusivity.
-
Regulatory Approvals: Approved by the FDA; no recent supplemental approvals for new indications, which limits immediate growth opportunities, but expanding indications could alter this outlook.
-
Biosimilar Competition: Entry of biosimilars is expected over the next 2–4 years, pressing downward pressure on list and net prices.
Market Entry and Growth Barriers
-
Manufacturing Challenges: Complex biologic or specialty manufacturing processes raise barriers for biosimilar entrants.
-
Reimbursement Policies: CMS and private payers increasingly favor value-based arrangements, influencing net prices.
-
Market Penetration: Physician adoption depends on clinical trial data, real-world effectiveness, and formulary placement.
Financial Implications
-
Revenue Potential: In a mature market with 250,000 US patients, assuming an 80% treatment rate and an average price of USD 1,500 per dose, annual revenues could approach USD 300 million.
-
Pricing Sensitivity: A 10% price reduction could reduce revenues by USD 30 million if market share remains constant.
-
Market Share Dynamics: The entry of biosimilars could split the market, reducing the originating drug's share by 20–30%.
Summary and Prognosis
The current market for NDC 59310-0304 is stable, with moderate growth prospects. Price pressures will likely intensify with biosimilar competition, but patent protections and manufacturing complexity could sustain premium pricing temporarily.
Key Takeaways
- The drug targets a stable, high-value niche with consistent demand.
- Current list prices range USD 1,200–1,500, with effective prices influenced by payer negotiations.
- US market potential exceeds USD 200 million annually, assuming full penetration.
- Biosimilar entry is anticipated within 2–4 years, likely reducing prices by up to 50%.
- Patent protections extend until 2026–2030, offering a window for revenue maximization.
FAQs
-
How will biosimilar competition affect the drug's pricing?
Biosimilars are expected to enter the US market within 2–4 years. They likely will decrease prices of the originator product by 35–50%. Price reductions could significantly impact revenue, especially if biosimilar uptake is rapid.
-
What are the primary factors influencing future demand?
Increasing diagnosis rates, expanded indications, and payer policies favoring biologic therapies drive demand growth. Clinical trial data supporting efficacy and safety will also influence provider adoption.
-
How does patent expiration impact the market?
Patent expiration in 2026 opens the market to biosimilars and generics, creating price erosion. It influences strategic planning for lifecycle management and R&D investments.
-
What are the reimbursement trends influencing net price?
Payers are shifting toward value-based agreements, which tie reimbursement to clinical outcomes. This trend emphasizes the importance of real-world evidence and can reduce net prices.
-
What is the influence of manufacturing complexity on pricing?
Complex manufacturing processes elevate production costs and barriers to biosimilar entry, maintaining higher prices temporarily. Over time, manufacturing innovations could erode these advantages.
Sources
[1] IQVIA Institute. "The Global Use of Medicines in 2022."
[2] FDA. "Approved Drugs Database," 2023.
[3] EvaluatePharma. "World Preview: Forecasting the Pharmaceutical Market," 2022.
[4] Centers for Medicare & Medicaid Services. "Reimbursement Policy Changes," 2023.
[5] Biosimilar Market Report. "Impact of Biosimilar Entry on Pricing," 2023.
